Misbadi (Dabigatran Etexilate)

Dabigatran etexilate, the active ingredient in Misbadi, is a direct thrombin inhibitor presented as an oral capsule for oral use. It is indicated for prevention of stroke and systemic embolism in patients with non‑valvular atrial fibrillation and for treatment and secondary prevention of deep vein thrombosis and pulmonary embolism.

GNH USA supplies Misbadi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Misbadi (dabigatran etexilate) is used in anticoagulation therapy to reduce thrombotic events in several cardiovascular conditions, particularly in adult patients safely. - Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism. - Deep vein thrombosis: treats acute DVT and helps prevent recurrence. - Pulmonary embolism: treats acute PE and reduces risk of recurrent embolic events. - Venous thromboembolism (VTE) prevention: maintains anticoagulation to lower incidence of new clots after initial therapy. - Secondary prevention of VTE: continues therapy to avoid repeat DVT or PE episodes.

Adverse reactions to Misbadi (dabigatran etexilate) are reported across clinical studies and post‑marketing surveillance.

Common Side Effects: - Dyspepsia: mild stomach discomfort, indigestion, or nausea. - Gastrointestinal bleeding: minor bleeding such as melena or occult blood loss. - Nosebleeds (epistaxis): occasional bleeding from the nasal passages. - Bruising: easy bruising of the skin after minor trauma. - Headache: transient, mild to moderate headache episodes.

Serious or Rare Side Effects: - Major bleeding: life‑threatening hemorrhage, including intracranial or gastrointestinal bleeding. - Hepatic injury: signs of liver dysfunction, such as elevated